The college of the Autorité des marchés financiers (AMF) on Friday demanded fines against the biotech AB Science, its CEO and a financial adviser for an amount of six million euros, in particular for transactions carried out during drug authorization processes.
Read alsoAB Science authorized by the USA to resume testing of its flagship molecule
During a public hearing before the AMF Sanctions Committee, the representative of the college requested a million euro fine against the French biotech for not having provided full information to investors. , three million against its CEO, Alain Moussy, and two million against a financial advisor for insider trading.